Association between immune-mediated cystitis and PD-1, PD-L1, CTLA-4, and LAG-3 immune checkpoint inhibitors: A pharmacovigilance study from the FAERS database.
Аннотация
BACKGROUND
Immune checkpoint inhibitors (ICIs) have transformed oncology but predispose patients to immune-related adverse events. Immune-mediated cystitis represents a rare yet clinically significant urological complication requiring enhanced surveillance. This studies characterizes the pharmacovigilance profile of immune-mediated cystitis across ICI classes using real-world post-market surveillance data.
PATIENTS AND
METHODS
This disproportionality analysis utilized the FDA Adverse Event Reporting System (FAERS) database, encompassing reports from Q4 2003 through Q3 2025. Fourteen ICIs were evaluated across four mechanistic classes: PD-1 (n = 7), PD-L1 (n = 4), CTLA-4 (n = 2), and LAG-3 (n = 1) inhibitors.
RESULTS
Among 14,104,743 adverse event reports, 69 cases of immune-mediated cystitis were identified. PD-1 inhibitors demonstrated the strongest signals: pembrolizumab (ROR 241.59; 95% CI 149.40-390.68; n = 28), nivolumab (ROR 118.56; 95% CI 68.56-205.02; n = 17), toripalimab (ROR 454.65; n = 2), and tislelizumab (ROR 266.31; n = 3). Ipilimumab exhibited robust disproportionality (ROR 297.28; 95% CI 167.73-526.89; n = 15). PD-L1 inhibitors showed minimal signals with isolated cases.
CONCLUSION
Immune-mediated cystitis demonstrates strongest association with PD-1 and CTLA-4 inhibitors, warranting enhanced clinical surveillance, prompt recognition, and evidence-based management protocols.
Предметные рубрики MeSH
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.